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evidence that they comprise the minimal machinery re-
quired for a complete RNAi response. In this study, the
authors identified only two proteins that specifically co-
purified with epitope-tagged hDcr: TRBP and hAgo2.
The purified ternary complex could be programmed
with either exogenous siRNA or unprocessed dsRNA to
recapitulate RNAi activity in vitro (Figure 1C). Thus, it
appears that the minimal RNAi machine in humans has
shrunk to the familiar trinity—hDcr, TRBP, and hAgo2—
though the participation of low-abundance copurifying
factors has not yet been categorically excluded. We
await the final nail in the coffin: the production of an
entirely recombinant human RNAi machine, which
should now be achievable.
The current study also bolsters the possibility that
hDcr/TRBP can play a role as a RISC-loading platform,
despite the fact that mammalian Dcr is not strictly re-
quired for an siRNA response (Kanellopoulou et al.,
2005; Murchison et al., 2005). In particular, Gregory et
al. (2005) found that the preassembled ternary complex
is significantly more potent when programmed with a
dsRNA processing substrate than with a “pre-diced”
duplex. Although this idea is not new (Rose et al., 2005
and references therein), this study adds biochemical
credence to the notion of direct coupling between
dsRNA processing and RISC loading as an autono-
mous function of hDcr/TRBP.
For its final trick, the minimal RNAi machine charac-
terized by Gregory et al. (2005) could take up an siRNA
and cleave a cognate target without the aid of ATP, sim-
ilar to the observations of Rand et al. (2005) in Drosoph-
ila S2 lysates. The authors estimate that, even in the
absence of ATP, the purified complex could carry out
multiple rounds of catalysis, though ATP boosted RISC
activity. Preliminary analyses with GTP, nonhydrolyz-
able ATP analogs, and even pyrophosphate and inor-
ganic phosphate indicate that we still have much to
learn about possible roles of NTP binding and hydroly-
sis in the human RNAi pathway.
Taken together, these three studies suggest a simpli-
fied view of siRNA-programmed RISC activation and
posit a minimal, three-component RNAi machine that
nominally fulfills the basic biochemical requirements of
a silencing response (dicing dsRNA, separating the two
strands, and executing multiple rounds of mRNA cleav-
age). Still, questions remain about accessory factors
that could serve to grease the machine’s wheels or
adapt it for multiple silencing outputs (Filipowicz, 2005).
Genetic and biochemical data have implicated a host
of proteins in both Drosophila and humans as compo-
nents of mature, active forms RISC. It remains to be
seen what new functions these other factors confer to
RNAi machines, and how they modulate the biochemi-
cal steps that are executed by the core Dicer/dsRBD
protein/Argonaute heterotrimer.
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Slugging It out: Fine Tuning
the p53-PUMA Death Connection
In response to DNA damage, the tumor suppressor
p53 elicits a complex cellular response. In this issue
of Cell, Wu et al. (2005) show that the transcription
factor SLUG is induced by p53 and protects hemato-
poietic progenitor cells from apoptosis triggered by
DNA damage. SLUG exerts this protective role by re-
pressing Puma, a proapoptotic target of p53. PUMA
is also a key coordinator of apoptosis mediated by
both nuclear and cytoplasmic functions of p53 (Chi-
puk et al., 2005).
The tumor suppressor p53 is frequently mutated in can-
cer cells, and its roles and regulation have been the
topic of much research and debate. p53 is a transcrip-
tion factor that is activated by cellular stress, leading to
increases in p53 mRNA translation (Takagi et al., 2005),
protein stability, and sequence-specific DNA binding
(reviewed in Yee and Vousden, 2005). Once activated,
p53 induces or represses various target genes, leading
to a myriad of cellular outcomes, including apoptosis,
growth arrest, cellular senescence, and DNA repair.
Thus, p53 integrates cellular stress responses, and loss
of p53 function leads to the aberrant proliferation of
damaged cells. p53 can be remarkably effective at
eliminating incipient cancer cells; however, inappropri-
ate or sustained p53 activation can damage normal tis-
sues and, in fact, may contribute to the aging of tissues
and organisms (Febeyre and Lowe, 2002). The p53 net-
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546work has therefore evolved a complex control system
that keeps p53 expressed and available when needed
but builds in safeguards that prevent “surges” in its net-
work from wreaking havoc on normal cells.
One important p53 effector is PUMA (p53-upregu-
lated modulator of apoptosis) (Yee and Vousden, 2005).
PUMA is a BH3-only member of the Bcl-2 family that is
a potent inducer of apoptosis mediated by p53. It initi-
ates the cell-death cascade by modulating Bax activity
to facilitate cytochrome c release from the mitochon-
dria. Its significance is underscored by the observation
that thymocytes from PUMA-deficient and p53-defi-
cient mice show comparable defects in apoptosis in-
duced by radiation. Additionally, suppression of PUMA,
like loss of p53, cooperates with Myc to promote the
formation of lymphomas. Two new reports highlight
how PUMA acts to fine tune and coordinate the p53
apoptotic network. In this issue of Cell, Wu, Look, and
coworkers (Wu et al., 2005) describe a new p53 target
gene, Slug, which acts as a transcriptional repressor of
Puma expression to antagonize apoptosis mediated by
p53. In a recent issue of Science, Chipuk et al. (2005)
identify a critical role for PUMA in mediating apoptosis
through both nuclear (transcription-dependent) and cy-
toplasmic (transcription-independent) functions of p53.
Look and colleagues (Inoue et al., 2002) originally
identified SLUG, a zinc-finger transcription factor, as a
downstream target of the oncogenic transcription fac-
tor E2A-HLF in human pro-B acute cell leukemia. They
showed that SLUG-deficient mice are radiosensitive
because their hematopoietic compartment fails to re-
generate following sublethal doses of radiation. Wu et
al. (2005) extend these findings by showing that SLUG
acts by repressing the transcriptional activation of
Puma by p53 and that loss of either p53 or PUMA res-
cues the radiosensitivity phenotype of SLUG-deficient
mice. Thus, the key factor that SLUG targets to protect
hematopoietic progenitors from DNA-damage-induced
programmed cell death is PUMA.
Dissection of apoptotic pathways that are conserved
in evolution provided important clues to elucidating the
action of SLUG. The Caenorhabditis elegans protein
CES-1 (SLUG homolog) acts in specific cell types to
inhibit EGL-1, a BH3-only proapoptotic protein (PUMA
homolog). ces-1 is transcriptionally repressed by CES-2,
a member of the bZIP family of transcription factors,
ultimately leading to cell death. E2A-HLF may promote
cancer by preventing the action of the putative ces-2
homolog, leading to more SLUG and aberrant pro-B cell
survival. There is likely to be a CES-2-like protein, pos-
sibly a tumor suppressor, that inhibits Slug in hemato-
poietic progenitor cells to allow for apoptosis of de-
fective pro-B cells. The definitive mammalian ces-2
homolog remains uncertain, although TEF and/or E4BP4
are candidates (Ikushima et al., 1997; Inukai et al., 2005).
Surprisingly, Wu et al. (2005) also show that Slug is a
p53 target gene. Thus, following DNA damage of hemato-
poietic progenitor cells, p53 not only upregulates Puma to
mediate apoptosis but simultaneously upregulates Slug.
SLUG represses Puma, thereby preventing apoptosis
(Figure 1). At first glance, these data are paradoxical: why
would p53, a protein known for its potent apoptotic activ-
ity, also promote cell survival? The authors propose that
hematopoietic progenitor cells, owing to their regenera-
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aive value to the organism, must be relatively protected
rom culling through p53-mediated apoptosis. The deci-
ion to arrest and repair or undergo apoptosis is con-
rolled by SLUG levels, and, consistent with this view,
LUG is expressed at lower levels in mature hematopoi-
tic cells that undergo apoptosis following DNA damage.
n addition to high endogenous amounts of the SLUG
rotein in hematopoietic progenitor cells, transactivation
f Slug by p53 may also contribute to the suppression of
uma transcription (Figure 1).
The duality of p53 pro- and antiapoptotic signaling on
he SLUG-PUMA connection may influence cell fate in the
ematopoietic system. However, p53 can simultaneously
romote cell death and survival through other mecha-
isms as well. In fact, the best characterized example of
53 “survival” signaling involves the ability of p53 to in-
uce Mdm2, a p53 ubiquitin ligase that acts in a negative-
eedback loop to terminate a p53 response (Yee and
ousden, 2005). Moreover, p53 activates “general” sur-
ival pathways, perhaps to alleviate the adverse effects
f DNA damage (Fang et al., 2001). Thus, by integrating
ell-type- or context-dependent layers of regulation into
he canonical death pathway, the system takes into ac-
ount different cellular needs and coordinates damage
esponses in the organism as a whole. Such dual signal-
ng appears to be a common theme in cell-death regula-
ion. For example, the apoptotic activity of tumor necrosis
actor (TNF) is balanced by the ability of TNF receptor
ignaling to simultaneously activate NF-κB, which acti-
ates targets important for cell survival (Aggarwal, 2003).
Whereas Wu et al. (2005) emphasize the intricacy with
hich p53 regulates cell-survival and cell-death decisions
hrough regulating Puma expression, Chipuk et al. (2005)
ighlight how PUMA coordinates the death process once
t is induced. Specifically, the authors report that PUMA
rovides a critical link that couples p53 transcription-
ependent and transcription-independent functions (Chi-
uk et al., 2005). In transcription-independent apoptosis,
53 in the cytoplasm directly binds to proapoptotic Bcl-
-family proteins, leading to permeabilization of mito-
hondria and apoptosis (Moll et al., 2005). Chipuk et
l. show that, after genotoxic stress, the antiapoptotic
rotein Bcl-xL sequesters cytoplasmic p53, whereas
uclear p53 induces transcription of Puma. PUMA then
inds to Bcl-xL and displaces p53, thereby allowing
53 to directly activate Bax and induce mitochondrial
ermeabilization and cell death. Importantly, the au-
hors showed that a mutant Bcl-xL impaired at binding
UMA but capable of binding p53 rendered cells resis-
ant to apoptosis mediated by p53.
These findings go a long way toward resolving a con-
roversy in the p53 field. The transcription-dependent
poptotic functions of p53 are well established in part
ecause p53 directly regulates so many genes linked
o the apoptotic process. Thus, p53 transcriptionally in-
uces proapoptotic members of the Bcl-2 family, com-
onents of death receptor signaling pathways, cell-
eath effectors, and negative regulators of cell-survival
athways (Yee and Vousden, 2005). Indeed, genetic
tudies demonstrating the importance of PUMA for
53-mediated cell death reinforce this view (Yee and
ousden, 2005). However, although evidence for tran-
cription-independent functions of p53 goes back over
decade, it is only recently that a plausible mechanism
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547Figure 1. Role of PUMA and SLUG in Modu-
lating Apoptosis Mediated by p53
Once activated by DNA damage, p53 in-
duces various target genes, including Puma
(which encodes a proapoptotic BH3-only
protein) and Slug (which encodes a tran-
scription factor that represses Puma tran-
scription). In most cells, the amount of SLUG
may not be sufficient to repress Puma and
prevent apoptosis. Importantly, in hemato-
poietic progenitor cells, the endogenous
amount of SLUG protein is sufficient to re-
press Puma and limit apoptosis induced by
DNA damage. Also shown is the role of
PUMA and p53 in coordinating cell death in
the cytoplasm. Here, PUMA binds Bcl-xL
and displaces p53, thereby allowing p53 to
directly activate Bax and induce permeabili-
zation of mitochondria and cell death.(direct targeting of mitochondria) has emerged (Moll et
al., 2005). However, genetic evidence was lacking. By
linking PUMA to the transcription-independent func-
tions of p53, Chipuk et al. (2005) associate the phenom-
enon with established genetics and reveal how the
transcription-dependent and -independent functions of
p53 act in concert to control apoptosis (Figure 1). Thus,
the role of Bcl-xL in preventing initiation of apoptosis at
the mitochondria is analogous to SLUG—each controls
PUMA to modulate the p53 response. It will be interest-
ing to determine whether the transcription-independent
function of p53 operates in hematopoietic progenitor
cells.
Despite the clear importance of PUMA in the p53-
mediated apoptotic program, p53 also targets other
apoptotic regulators, including NOXA and BAX (Yee
and Vousden, 2005). Although none have been as
strongly linked to apoptosis as PUMA, it seems unlikely
that the system would have evolved to target so many
irrelevant genes. Perhaps p53 targets multiple steps in
the apoptotic cascade to ensure that cell death pro-
ceeds efficiently. And given that each of these effectors
is also embedded in other signaling networks, the deci-
sive mediators of p53 action may be influenced by
other cell type and microenvironment factors that im-
pact these components. For example, factors influenc-
ing the levels of SLUG, Bcl-xL, or PUMA may alter the
importance of other p53 effectors in a given cell-death
program or may dictate the balance between apoptosis
mediated by p53 and its other effector functions.Finally, these results suggest ways to modulate the
p53 pathway for therapeutic purposes. For example,
based on insights from Chipuk et al. (2005) and others,
one would predict that, in tumors with wild-type p53,
the overexpression of a peptide consisting of the do-
main in PUMA that mediates interaction with Bcl-xL,
the BH3 domain, would sequester Bcl-xL, thereby re-
leasing p53 to induce cell death. The data of Wu et al.
(2005) provide another example of a potential therapeu-
tic application. Their data suggest that increasing the
amount of SLUG to inhibit apoptosis may be a good strat-
egy to circumvent the death of hematopoietic stem cells
and progenitors induced by chemotherapy. Of note, the
induction of apoptosis by p53 in normal tissues is respon-
sible for some side effects of DNA-damaging chemother-
apeutic agents, and p53 inhibitors have been developed
to thwart these effects (Komarov et al., 1999). Although
such drugs should have no effect on tumors bearing a
mutant form of p53 and should reduce the dose-limiting
toxicities of chemotherapy, there are concerns that
these such therapies would be mutagenic because
they would also disable p53 checkpoint functions. Al-
ternatively, activation of the SLUG pathway would pre-
vent apoptosis without compromising repair and, in
principle, provide a less mutagenic strategy to achieve
similar ends. A limitation to such therapy is that the
SLUG pathway may also be activated in tumor cells
and consequently may confer resistance to chemother-
apeutic agents. Further insights into the complexities of
p53 regulation will eventually provide a foothold toward
Cell
548exploiting this potent tumor-suppressor network for
treating cancer.
Jack T. Zilfou, Mona S. Spector, and Scott W. Lowe
Cold Spring Harbor Laboratory
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